BioSpace News Archive

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to three new employees with grant dates of May 1, 2020 and May 4, 2020, as an equity inducement award outside of the company’s 2017 Stock Incentive Plan and material to the employee’s acceptance of employment with the company.

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three months ended March 31, 2020.

Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel, small-molecule drugs for the treatment of cancer and other life-threatening diseases, announced its financial results for the first quarter ended March 31, 2020.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, announced financial results for the quarter ended March 31, 2020, as well as recent business highlights.

Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $20.1 million in first quarter 2020

Sol-Gel Technologies, Ltd., a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report its first quarter 2020 financial results and operational highlights on Thursday, May 14, 2020 at 7:05 AM ET.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, reported its financial results for the three months ended March 31, 2020 and provided a business update.

Important progress advancing COVID-19 STARR™ mRNA vaccine candidate (LUNAR-COV19); New preclinical data demonstrate robust immunogenicitywith a single, low dose

BioDelivery Sciences International, Inc., a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, reported strong financial results for the first quarter ended March 31, 2020, as well as the following operational and performance highlights.

Enrollment on track in Controlled IL-12 phase 2 clinical trial with Regeneron’s Libtayo®; Controlled IL-12 clinical data update at ASCO 2020